Telix Pharmaceuticals (TLPPF) Total Debt (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Total Debt for 4 consecutive years, with $516.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt changed N/A year-over-year to $516.4 million in Q2 2026; TTM through Jun 2026 was $516.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $405.0 million, up 8.5% from the prior year.
• Total Debt was $516.4 million for Q2 2026 at Telix Pharmaceuticals, up from $405.0 million in the prior quarter.
• Over five years, Total Debt peaked at $516.4 million in Q2 2026 and troughed at $6.0 million in Q4 2023.
• A 4-year average of $325.2 million and a median of $389.2 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 6151.08% in 2024 and increased 8.5% in 2025, its largest moves.
• Over 4 years, Total Debt stood at $6.0 million in 2023, then surged by 6151.08% to $373.3 million in 2024, then climbed by 8.5% to $405.0 million in 2025, then increased by 27.49% to $516.4 million in 2026.
• The last three Total Debt figures came in at $516.4 million (Q2 2026), $405.0 million (Q4 2025), and $373.3 million (Q4 2024), per Business Quant data.